SUTs are a well-established choice for large and commercial-scale biopharmaceutical production. The choice between SSBs and stainless steel bioreactors is dependent on each biomanufacturer’s unique scenario, including molecule type, range of titer, cell density, operational equivalence and scale limitations. This can lead to faster turnaround and greater productivity.